Abnormalities of the long arm of chromosome 21 in 107 patients with hematopoietic disorders: a collaborative retrospective study of the Groupe Français de Cytogénétique Hématologique

Cancer Genetics and Cytogenetics
Eric JeandidierGroupe Français de Cytogénétique Hématologique (GFCH)

Abstract

Chromosome 21 is frequently rearranged in hematopoietic malignancies. In order to detect new chromosomal aberrations, the Groupe Français de Cytogénétique Hématologique collected a series of 107 patients with various hematologic disorders and acquired structural abnormalities of the long arm of chromosome 21. The abnormalities were subclassified into 10 groups, according to the location of the 21q breakpoint and the type of abnormality. Band 21q22 was implicated in 72 patients (excluding duplications, triplications, and amplifications). The involvement of the RUNX1 gene was confirmed in 10 novel translocations, but the gene partners were not identified. Eleven novel translocations rearranging band 21q22 with bands 1q25, 2p21, 2q37, 3p21, 3p23, 4q31, 6p24 approximately p25, 6p12, 7p15, 16p11, and 18q21 were detected. Rearrangements of band 21q11 and 21q21 were detected in six novel translocations with 5p15, 6p21, 15q21, 16p13, and 20q11 and with 1p33, 3q27, 5p14, 11q11, and 14q11, respectively. Duplications, triplications, amplifications, and isodicentric chromosomes were detected in eight, three, eight, and three patients, respectively. The present study shows both the wide distribution of the breakpoints on the long arm of chr...Continue Reading

Citations

Dec 23, 2010·Future Oncology·Etienne De BraekeleerMarc De Braekeleer
Nov 9, 2010·Leukemia & Lymphoma·Anastasia AthanasiadouAchilles Anagnostopoulos
Jul 29, 2008·Cancer Genetics and Cytogenetics·Etienne De BraekeleerMarc De Braekeleer
Nov 6, 2007·Cancer Genetics and Cytogenetics·Mai TakeuchiToshimitsu Matsui
Jul 1, 2009·British Journal of Haematology·Hetal Patel, Myrtle Y Gordon
Feb 11, 2018·Annals of Hematology·Elena ZerkalenkovaYulia Olshanskaya
Jun 10, 2008·Orvosi hetilap·Irén HaltrichGyörgy Fekete
Feb 21, 2008·Acta Haematologica·Christie L Boils, Anwar N Mohamed

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.